Alphabetical listing of all products

Prices
  • 5 mg - 95 EUR
  • 25 mg - 340 EUR
  • 100 mg - 460 EUR

Lenvatinib

Lenvatinib is an orally available multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases. IC50 values are in a nanomolar range: 22 nM for VEGFR1, 4 nM for VEGFR2, 5 nM for VEGFR3, 46 nM for FGFR1, 51 nM for PDGFRa, 39 nM for PDGFRb and 100 nM for KIT. Co-crystal structure analysis suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several other VEGFR2 kinase inhibitors.

catalogue number: L171
synonyms: E7080
CAS: 417716-92-8
MW: 426.85 g/mol

References
Int J Cancer. 2008 Feb 1;122(3):664-71 PMID: 17943726
Mol Cancer Ther. 2011 Jul;10(7):1218-28 PMID: 21551260
ACS Med Chem Lett. 2014 Nov 17;6(1):89-94 PMID: 25589937